

SEQUENCE LISTING



(1) GENERAL INFORMATION:

- 70510
- (i) APPLICANT: Gorman, Daniel M.
Mattson, Jeanine D.
 - (ii) TITLE OF INVENTION: Mammalian Cell Surface Antigens; Related Reagents
 - (iii) NUMBER OF SEQUENCES: 2
 - (iv) CORRESPONDENCE ADDRESS:
 - (A) ADDRESSEE: DNAX Research Institute
 - (B) STREET: 901 California Avenue
 - (C) CITY: Palo Alto
 - (D) STATE: California
 - (E) COUNTRY: USA
 - (F) ZIP: 94304-1104
 - (v) COMPUTER READABLE FORM:
 - (A) MEDIUM TYPE: Floppy disk
 - (B) COMPUTER: IBM PC compatible
 - (C) OPERATING SYSTEM: PC-DOS/MS-DOS
 - (D) SOFTWARE: PatentIn Release #1.0, Version #1.30
 - (vi) CURRENT APPLICATION DATA:
 - (A) APPLICATION NUMBER: US
 - (B) FILING DATE: 12-DEC-1997
 - (C) CLASSIFICATION:
 - (vii) PRIOR APPLICATION DATA:
 - (A) APPLICATION NUMBER: US 60/032,846
 - (B) FILING DATE: 13-DEC-1996
 - (viii) ATTORNEY/AGENT INFORMATION:
 - (A) NAME: Ching, Edwin P.
 - (B) REGISTRATION NUMBER: 34,090
 - (C) REFERENCE/DOCKET NUMBER: DX0686
 - (ix) TELECOMMUNICATION INFORMATION:
 - (A) TELEPHONE: (650)852-9196
 - (B) TELEFAX: (650)496-1204

(2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 2191 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: cDNA
- (ix) FEATURE:

(A) NAME/KEY: CDS
(B) LOCATION: 125..1072

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

GCCAGGACCT CTGTGAACCG GTCGGGGCGG GGGCCGCTG GCCGGGAGTC TGCTCGGCGG	60
TGGGTGGCCG AGGAAGGGAG AGAACGATCG CGGAGCAGGG CGCCCGAACT CCGGGCGCCG	120
CGCC ATG CGC CGG GCC AGC CGA GAC TAC GGC AAG TAC CTG CGC AGC TCG Met Arg Arg Ala Ser Arg Asp Tyr Gly Lys Tyr Leu Arg Ser Ser	169
1 5 10 15	
GAG GAG ATG GGC AGC GGC CCC GGC GTC CCA CAC GAG GGT CCG CTG CAC Glu Glu Met Gly Ser Gly Pro Gly Val Pro His Glu Gly Pro Leu His	217
20 25 30	
CCC GCG CCT TCT GCA CCG GCT CCG GCG CCG CCA CCC GCC GCC TCC CGC Pro Ala Pro Ser Ala Pro Ala Pro Ala Pro Pro Pro Ala Ala Ser Arg	265
35 40 45	
TCC ATG TTC CTG GCC CTC CTG GGG CTG GGA CTG GGC CAG GTG GTC TGC Ser Met Phe Leu Ala Leu Leu Gly Leu Gly Leu Gly Gln Val Val Cys	313
50 55 60	
AGC ATC GCT CTG TTC CTG TAC TTT CGA GCG CAG ATG GAT CCT AAC AGA Ser Ile Ala Leu Phe Leu Tyr Phe Arg Ala Gln Met Asp Pro Asn Arg	361
65 70 75	
ATA TCA GAA GAC AGC ACT CAC TGC TTT TAT AGA ATC CTG AGA CTC CAT Ile Ser Glu Asp Ser Thr His Cys Phe Tyr Arg Ile Leu Arg Leu His	409
80 85 90 95	
GAA AAC GCA GGT TTG CAG GAC TCG ACT CTG GAG AGT GAA GAC ACA CTA Glu Asn Ala Gly Leu Gln Asp Ser Thr Leu Glu Ser Glu Asp Thr Leu	457
100 105 110	
CCT GAC TCC TGC AGG AGG ATG AAA CAA GCC TTT CAG GGG GCC GTG CAG Pro Asp Ser Cys Arg Arg Met Lys Gln Ala Phe Gln Gly Ala Val Gln	505
115 120 125	
AAG GAA CTG CAA CAC ATT GTG GGG CCA CAG CGC TTC TCA GGA GCT CCA Lys Glu Leu Gln His Ile Val Gly Pro Gln Arg Phe Ser Gly Ala Pro	553
130 135 140	
GCT ATG ATG GAA GGC TCA TGG TTG GAT GTG GCC CAG CGA GGC AAG CCT Ala Met Met Glu Gly Ser Trp Leu Asp Val Ala Gln Arg Gly Lys Pro	601
145 150 155	
GAG GCC CAG CCA TTT GCA CAC CTC ACC ATC AAT GCT GCC AGC ATC CCA Glu Ala Gln Pro Phe Ala His Leu Thr Ile Asn Ala Ala Ser Ile Pro	649
160 165 170 175	
TCG GGT TCC CAT AAA GTC ACT CTG TCC TCT TGG TAC CAC GAT CGA GGC Ser Gly Ser His Lys Val Thr Leu Ser Ser Trp Tyr His Asp Arg Gly	697
180 185 190	

TGG GCC AAG ATC TCT AAC ATG ACG TTA AGC AAC GGA AAA CTA AGG GTT	745
Trp Ala Lys Ile Ser Asn Met Thr Leu Ser Asn Gly Lys Leu Arg Val	
195 200 205	
AAC CAA GAT GGC TTC TAT TAC CTG TAC GCC AAC ATT TGC TTT CGG CAT	793
Asn Gln Asp Gly Phe Tyr Tyr Leu Tyr Ala Asn Ile Cys Phe Arg His	
210 215 220	
CAT GAA ACA TCG GGA AGC GTA CCT ACA GAC TAT CTT CAG CTG ATG GTG	841
His Glu Thr Ser Gly Ser Val Pro Thr Asp Tyr Leu Gln Leu Met Val	
225 230 235	
TAT GTC GTT AAA ACC AGC ATC AAA ATC CCA AGT TCT CAT AAC CTG ATG	889
Tyr Val Val Lys Thr Ser Ile Lys Ile Pro Ser Ser His Asn Leu Met	
240 245 250 255	
AAA GGA GGG AGC ACG AAA AAC TGG TCG GGC AAT TCT GAA TTC CAC TTT	937
Lys Gly Gly Ser Thr Lys Asn Trp Ser Gly Asn Ser Glu Phe His Phe	
260 265 270	
TAT TCC ATA AAT GTT GGG GGA TTT TTC AAG CTC CGA GCT GGT GAA GAA	985
Tyr Ser Ile Asn Val Gly Gly Phe Phe Lys Leu Arg Ala Gly Glu Glu	
275 280 285	
ATT AGC ATT CAG GTG TCC AAC CCT TCC CTG CTG GAT CCG GAT CAA GAT	1033
Ile Ser Ile Gln Val Ser Asn Pro Ser Leu Leu Asp Pro Asp Gln Asp	
290 295 300	
GCG ACG TAC TTT GGG GCT TTC AAA GTT CAG GAC ATA GAC TGAGACTCAT	1082
Ala Thr Tyr Phe Gly Ala Phe Lys Val Gln Asp Ile Asp	
305 310 315	
TTCGTGGAAC ATTAGCATGG ATGTCCTAGA TGTTTGAAAA CTTCTTAAAA AATGGATGAT	1142
GTCTATACAT GTGTAAGACT ACTAAGAGAC ATGGCCCACG GTGTATGAAA CTCACAGCCC	1202
TCTCTCTTGA GCCTGTACAG GTTGTGTATA TGTAAGTCC ATAGGTGATG TTAGATTTCAT	1262
GGTGATTACA CAACGGTTTTT ACAATTTTGT AATGATTTCC TAAGAATTGA ACCAGATTGG	1322
GAGAGGTATT CCGATGCTTA TGAAAACTT ACACGTGAGC TATGGAAGGG GGTCACAGTC	1382
TCTGGGTCTA ACCCCTGGAC ATGTGCCACT GAGAACCTTG AAATTAAGAA GATGCCATGT	1442
CATTGCAAAG AAATGATAGT GTGAAGGGTT AAGTTCTTTT GAATTGTTAC ATTGCGCTGG	1502
GACCTGCAAA TAAGTTCTTT TTTTCTAATG AGGAGAGAAA AATATATGTA TTTTATATA	1562
ATGTCTAAAG TTATATTTCA GGTGTAATGT TTTCTGTGCA AAGTTTTGTA AATTATATTT	1622
GTGCTATAGT ATTTGATTCA AAATATTTAA AAATGTCTCA CTGTTGACAT ATTTAATGTT	1682
TTAAATGTAC AGATGTATTT AACTGGTGCA CTTTGTAATT CCCCTGAAGG TACTCGTAGC	1742
TAAGGGGGCA GAATACTGTT TCTGGTGACC ACATGTAGTT TATTTCTTTA TTCTTTTAA	1802
CTTAATAGAG TCTTCAGACT TGTCAAAACT ATGCAAGCAA AATAAATAAA TAAAAATAAA	1862

ATGAATATCT TGAATAATAA GTAGGATGTT GGTACCAGG TGCCTTTCAA ATTTAGAAGC 1922
 TAATTGACTT TAGGAGCTGA CATAGCCAAA AAGGATACAT AATAGGCTAC TGAAAATCTG 1982
 TCAGGAGTAT TTATGCAATT ATTGAACAGG TGTCTTTTTT TACAAGAGCT ACAAATTGTA 2042
 AATTTTGTTC CTTTTTTTTC CCATAGAAAA TGTACTATAG TTTATCAGCC AAAAAACAAT 2102
 CCACTTTTTC ATTTAGTGAA AGTTATTTTA TTATACTGTA CAATAAAAGC ATTGTTTCTG 2162
 AATGGCATT TTTGGTACTT AAAAAATGGC 2191

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 316 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Met	Arg	Arg	Ala	Ser	Arg	Asp	Tyr	Gly	Lys	Tyr	Leu	Arg	Ser	Ser	Glu	1	5	10	15
Glu	Met	Gly	Ser	Gly	Pro	Gly	Val	Pro	His	Glu	Gly	Pro	Leu	His	Pro	20	25	30	
Ala	Pro	Ser	Ala	Pro	Ala	Pro	Ala	Pro	Pro	Pro	Ala	Ala	Ser	Arg	Ser	35	40	45	
Met	Phe	Leu	Ala	Leu	Leu	Gly	Leu	Gly	Leu	Gly	Gln	Val	Val	Cys	Ser	50	55	60	
Ile	Ala	Leu	Phe	Leu	Tyr	Phe	Arg	Ala	Gln	Met	Asp	Pro	Asn	Arg	Ile	65	70	75	80
Ser	Glu	Asp	Ser	Thr	His	Cys	Phe	Tyr	Arg	Ile	Leu	Arg	Leu	His	Glu	85	90	95	
Asn	Ala	Gly	Leu	Gln	Asp	Ser	Thr	Leu	Glu	Ser	Glu	Asp	Thr	Leu	Pro	100	105	110	
Asp	Ser	Cys	Arg	Arg	Met	Lys	Gln	Ala	Phe	Gln	Gly	Ala	Val	Gln	Lys	115	120	125	
Glu	Leu	Gln	His	Ile	Val	Gly	Pro	Gln	Arg	Phe	Ser	Gly	Ala	Pro	Ala	130	135	140	
Met	Met	Glu	Gly	Ser	Trp	Leu	Asp	Val	Ala	Gln	Arg	Gly	Lys	Pro	Glu	145	150	155	160
Ala	Gln	Pro	Phe	Ala	His	Leu	Thr	Ile	Asn	Ala	Ala	Ser	Ile	Pro	Ser	165	170	175	
Gly	Ser	His	Lys	Val	Thr	Leu	Ser	Ser	Trp	Tyr	His	Asp	Arg	Gly	Trp				

180	185	190
Ala Lys Ile Ser Asn Met Thr Leu Ser Asn Gly Lys Leu Arg Val Asn		
195	200	205
Gln Asp Gly Phe Tyr Tyr Leu Tyr Ala Asn Ile Cys Phe Arg His His		
210	215	220
Glu Thr Ser Gly Ser Val Pro Thr Asp Tyr Leu Gln Leu Met Val Tyr		
225	230	235
Val Val Lys Thr Ser Ile Lys Ile Pro Ser Ser His Asn Leu Met Lys		
245	250	255
Gly Gly Ser Thr Lys Asn Trp Ser Gly Asn Ser Glu Phe His Phe Tyr		
260	265	270
Ser Ile Asn Val Gly Gly Phe Phe Lys Leu Arg Ala Gly Glu Glu Ile		
275	280	285
Ser Ile Gln Val Ser Asn Pro Ser Leu Leu Asp Pro Asp Gln Asp Ala		
290	295	300
Thr Tyr Phe Gly Ala Phe Lys Val Gln Asp Ile Asp		
305	310	315

55

Application No.: 08/989,362

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s)



- ☐ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☒ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other: _____

Applicant Must Provide:

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-1123

For CRF Submission Help, call (703) 308-4212

For PatentIn software help, call (703) 308-0400

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE